Axsome Therapeutics, Inc. (AXSM): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Axsome Therapeutics, Inc. (AXSM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 axsm-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 Axsome Therapeutics, Inc. Executive Severance and Change in Control Plan ARTICLE I Statement of Purpose and Effective Date 1.01 Purpose . Axsome Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ Axsome ”), here
How this was made
The 30-second read
Why it matters
The Plan is intended to retain/motivate key employees by reducing concerns about involuntary termination, and it supersedes prior severance arrangements for covered matters.
Market read
This is a governance/compensation disclosure; without accompanying clinical, regulatory, or financial updates, it is unlikely to drive a major repricing.
What to watch
Traders may want to check the full 8-K for any named officer/director departures or appointments tied to the plan, since Item 5.02 can include personnel changes beyond the severance document.
Background
The SEC 8-K Item 5.02 includes executive severance and change-in-control compensation arrangements; the exhibit describes the Plan’s purpose and effective date.
Ticker impact
Axsome Therapeutics filed an 8-K exhibit establishing an Executive Severance and Change in Control Plan effective June 5, 2026.
Likely limited immediate price impact; any reaction would be secondary to broader AXSM fundamentals.
This is an SEC EDGAR 8-K with a compensation plan description (severance/change-in-control framework) rather than new operating results, trial data, or regulatory/product events.
Market effects
Minimal; executive severance/change-in-control plan filings are common across biotech and generally do not signal pipeline changes.
None.
None.
Counterpoint
If the plan materially increases change-in-control payouts or signals upcoming leadership transitions, it could become a sentiment overhang—though this excerpt does not quantify incremental cost.
Key entities
- issuerAxsome Therapeutics, Inc.
Company establishing the Executive Severance and Change in Control Plan via an 8-K exhibit.
